Examples of Customized Solutions


Organoid-based fibroblast co-culture for inflammatory bowel disease

The prevailing model of Inflammatory Bowel Disease (IBD) is characterized by chronic inflammation and a dysfunctional epithelial barrier. However, conventional frontline treatments targeting chronic inflammation have limited effectiveness, leaving many patients without relief. Recent research highlights the role of pro-inflammatory fibroblasts in the chronicity of IBD. However, conventional preclinical models do not accurately recapitulate the dynamics of the human intestinal niche. To bridge this gap, we developed an innovative co-culture platform using IBD patient-derived organoids and fibroblasts.

This groundbreaking solution allows for the observation and analysis of the intricate interactions between pro-inflammatory fibroblasts and epithelial cells, uncovering valuable insights into the disease mechanisms. Additionally, our reproducible system enables the screening of compounds that target these critical cell interactions. Through our tailored approach, we provide a unique solution that empowers researchers to test their unconventional hypothesis in a clinically relevant model, unlocking new possibilities for effective IBD treatments.

Basket screen for evaluating the efficacy of engineered T cell

With Gadeta’s groundbreaking engineered T-cell product demonstrating wide tumor specificity and a favorable safety profile in hematological cancer, they sought to extend its application to solid tumors. In response, we devised an innovative approach known as the basket trial, leveraging patient-derived organoids (PDOs) from diverse solid tumor types, including breast, colon, lungs, head and neck, ovary, and pancreas. This patient-representative platform enabled the acquisition of comprehensive preclinical data, allowing for a thorough assessment of the therapeutic efficacy of their T-cell product across various tissue types. By implementing the basket screen approach, we empowered our clients to pinpoint a specific indication that merited further therapeutic evaluation, enabling us to provide precisely tailored solutions that meet their distinct requirements.



Recapitulate host-pathogen interactions

Pks E. coli, a prevalent bacterial strain in colorectal patients’ gut, has been associated with DNA damage. The question of whether this bacterium plays a causal role in disease onset has long been debated. In 2020, Pleguezuelos-Manzano et al. conducted a study where healthy tissue-derived organoids were repeatedly infected with pks E. coli using microinjection. The results revealed that the organoids acquired a mutational signature found in cancer patients, indicating that this bacterium indeed has a causative role in the diseases and contributes to clinically relevant mutations. To investigate this further, we developed a co-culture system that accurately replicated the pathogenic interactions between the bacteria and epithelial cells. Additionally, we established a medium to high-throughput screening platform on this co-culture system, facilitating the testing of novel therapeutic agents.

Embrace the potential of patient-derived organoid technology and propel your research forward today!

speak to an expert

Want to know more?


First clinical candidate developed using HUB Organoids makes it to the clinical trials within five years

read more


Accelerating oncology drug discovery using HUB Organoids

download now


Patient-derived organoids predict clinical response: a patient in the lab

download now

Get in touch

Discover the transformative potential of our technology with a free consultation with an expert

Have any questions?

contact us